DK1408966T3 - Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes - Google Patents

Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes

Info

Publication number
DK1408966T3
DK1408966T3 DK02751454T DK02751454T DK1408966T3 DK 1408966 T3 DK1408966 T3 DK 1408966T3 DK 02751454 T DK02751454 T DK 02751454T DK 02751454 T DK02751454 T DK 02751454T DK 1408966 T3 DK1408966 T3 DK 1408966T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
diabetes
pharmaceutical combinations
synergistic pharmaceutical
Prior art date
Application number
DK02751454T
Other languages
Danish (da)
English (en)
Inventor
Gyoergy Rabloczky
Zoltan Szilvassy
Nagy Peter Literati
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0102982A external-priority patent/HU0102982D0/hu
Priority claimed from HU0202204A external-priority patent/HU226244B1/hu
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Application granted granted Critical
Publication of DK1408966T3 publication Critical patent/DK1408966T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyridine Compounds (AREA)
DK02751454T 2001-07-17 2002-07-10 Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes DK1408966T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0102982A HU0102982D0 (en) 2001-07-17 2001-07-17 Synergic pharmaceutical composition
HU0202204A HU226244B1 (hu) 2002-07-05 2002-07-05 Gyógyszer-kombináció a diabétesz megelõzésére vagy kezelésére
PCT/HU2002/000067 WO2003007951A1 (en) 2001-07-17 2002-07-10 A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Publications (1)

Publication Number Publication Date
DK1408966T3 true DK1408966T3 (da) 2008-06-16

Family

ID=89980599

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02751454T DK1408966T3 (da) 2001-07-17 2002-07-10 Synergistiske farmaceutiske kombinationer til forebyggelse eller behandling af diabetes

Country Status (21)

Country Link
US (2) US7635674B2 (de)
EP (1) EP1408966B1 (de)
JP (1) JP4598390B2 (de)
KR (1) KR100920560B1 (de)
CN (1) CN1270713C (de)
AT (1) ATE386523T1 (de)
AU (1) AU2002354884B2 (de)
BR (1) BR0210744A (de)
CA (2) CA2682251A1 (de)
CY (1) CY1107939T1 (de)
DE (1) DE60225143T2 (de)
DK (1) DK1408966T3 (de)
ES (1) ES2300460T3 (de)
IL (2) IL159412A0 (de)
MX (1) MXPA04000324A (de)
NO (1) NO20040153L (de)
NZ (1) NZ531155A (de)
PL (1) PL205826B1 (de)
PT (1) PT1408966E (de)
RU (1) RU2311907C2 (de)
WO (1) WO2003007951A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060089325A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of PTP1B expression
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
ES2355680T3 (es) * 2006-11-02 2011-03-30 N-Gene Research Laboratories Inc. Reducción del sobrepeso o de la obesidad.
CN101594868B (zh) * 2006-11-02 2012-12-12 N基因研究实验室公司 具有抗精神病、抗抑郁或抗癫痫活性以及较小副作用的药物组合物
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
US20080208328A1 (en) * 2007-02-23 2008-08-28 Endovalve, Inc. Systems and Methods For Placement of Valve Prosthesis System
UA98799C2 (ru) 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
JP5812318B2 (ja) * 2007-12-04 2015-11-11 レメディー ファーマシューティカルズ， インコーポレイテッド 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
WO2009074835A1 (en) * 2007-12-10 2009-06-18 N-Gene Research Laboratories Inc. Dose reduction of a cannabinoid cb1 receptor antagonist in the treatment of overweight or obesity
CN105886506A (zh) 2011-04-13 2016-08-24 Isis制药公司 Ptp1b 表达的反义调节
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN105476995A (zh) * 2015-12-23 2016-04-13 青岛海之源智能技术有限公司 一种二甲双胍阿昔莫司复方缓释胶囊及制备方法
PH12019502776A1 (en) 2017-06-30 2020-10-26 Univ California Compositions and methods for modulating hair growth
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN115916202A (zh) * 2020-05-27 2023-04-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂瑞拉可兰和cyp2c9底物的并行给药
US12559490B2 (en) 2020-06-30 2026-02-24 The Regents Of The University Of California Compositions and methods for modulating hair growth

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6291495B1 (en) * 1997-02-24 2001-09-18 Robert B. Rieveley Method and composition for the treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6121278A (en) * 1997-09-03 2000-09-19 Guilford Pharmaceuticals, Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO2000007580A2 (en) 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
UA65635C2 (uk) 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ

Also Published As

Publication number Publication date
CA2452558C (en) 2009-12-22
ES2300460T3 (es) 2008-06-16
CN1531433A (zh) 2004-09-22
WO2003007951A1 (en) 2003-01-30
BR0210744A (pt) 2004-07-20
RU2311907C2 (ru) 2007-12-10
PT1408966E (pt) 2008-05-02
JP4598390B2 (ja) 2010-12-15
CA2452558A1 (en) 2003-01-30
DE60225143T2 (de) 2009-02-12
US20100048627A1 (en) 2010-02-25
EP1408966A1 (de) 2004-04-21
CA2682251A1 (en) 2003-01-30
MXPA04000324A (es) 2004-07-23
NO20040153L (no) 2004-03-16
US20070015687A1 (en) 2007-01-18
EP1408966B1 (de) 2008-02-20
AU2002354884B2 (en) 2007-10-18
AU2002354884A2 (en) 2003-03-03
NZ531155A (en) 2005-07-29
CN1270713C (zh) 2006-08-23
KR20040029371A (ko) 2004-04-06
KR100920560B1 (ko) 2009-10-08
JP2004537550A (ja) 2004-12-16
US7635674B2 (en) 2009-12-22
ATE386523T1 (de) 2008-03-15
RU2004105149A (ru) 2005-04-20
IL159412A0 (en) 2004-06-01
PL205826B1 (pl) 2010-05-31
CY1107939T1 (el) 2013-09-04
PL364662A1 (en) 2004-12-13
DE60225143D1 (de) 2008-04-03
IL159412A (en) 2009-09-22
US8048873B2 (en) 2011-11-01

Similar Documents

Publication Publication Date Title
NO20040153L (no) Synergistisk farmasoytisk kombinasjon for profylakse eller behandling av diabetes
WO2001081310A8 (en) 1-aroyl-piperidinyl benzamidines
WO1999063826A3 (de) Mittel zur bekämpfung von pflanzenschädlingen
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
NO20032488D0 (no) Orto-substituerte nitrogen-inneholdende bisarylforbindelser anvendt som kaliumkanalinhibitorer
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
NO20034660L (no) Spiropyrazolforbindelser, farmasoytiske preparater som omfatter en slik forbindelse, og anvendelse av forbindelsene for fremstilling av farmasoytiske preparater
SE0201544D0 (sv) Novel compounds and thier use
WO2004082581A3 (fr) Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives
NO20065075L (no) Ikke-nukleosidbaserte revers-transkriptase-inhibitorer.
PY0000170A (es) 2-(hydroxyo-n-(5-nitor-2-thiazolyl) benzamide
NO20054787D0 (no) Indenderivater som farmasotiske midler
DK1142573T3 (da) Farmaceutiske præparater omfattende faropenem-natrium og en diaminacetatforbindelse til forbedring af absorption i mave-tarm-kanalen
TR200003156T2 (tr) Bir aktif içerik olarak izomalt içeren terapötik soğuk algınlığına karşı ajan.
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
IL159841A0 (en) Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions
UA81608C2 (ru) Синергическая фармацевтическая комбинация для профилактики или лечения диабета
TR200100906T2 (tr) Trombin inhibitörleri olarak benzamid türevleri
TW200640464A (en) Pharmaceutical composition comprising phenoxazinium compounds as an active ingredient
DK1610785T3 (da) Farmaceutisk kombination til behandlingen af spasticitet og/eller smerte
BRPI0406580A (pt) Uso de carbamato de (s)-n-etil-n-metil-3-[1-(dimetilamino)etil]-fenil, uso de um ou mais ingredientes ativos e medicamento para a profilaxia de envenenamento por inibidores de colinesterase